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ABSTRACT  
Though considered as an inflammation marker, exhaled nitric oxide (FENO) was shown to be 
sensitive to airway caliber changes to such an extent that it might be considered as a marker of 
them. It is thus important to understand how these changes and their localization mechanically 
affect the total NO flux penetrating the airway lumen (JawNO), hence FENO, independently 
from any inflammatory status change. 
A new model was used which simulates NO production, consumption and diffusion inside the 
airway epithelium wall, then, NO excretion through the epithelial wall into the airway lumen 
and, finally, its axial transport by diffusion and convection in the airway lumen. This model 
may also consider the presence of a mucus layer coating the epithelial wall. 
Simulations were performed that showed the great sensitivity of JawNO to peripheral airways 
caliber changes. Moreover, FENO showed distinct behaviors depending on the location of the 
caliber change. Considering a bronchodilation, absence of FENO change was associated with 
dilation of central airways, FENO increase with dilation up to pre-acinar small airways, and 
FENO decrease with intra-acinar dilation due to amplification of the back-diffusion flux. The 
presence of a mucus layer was also shown to play a significant role in FENO changes. 
Altogether, the present work provides theoretical evidences that specific FENO changes in 
acute situations are linked to specifically located airway caliber changes in the lung periphery. 
This opens the way for a new role for FENO as a functional marker of peripheral airway 
caliber change. 
NEW AND NOTEWORTHY 
Using a new model of NO production and transport allowing realistic simulation of airways 
caliber change, the present work provides theoretical evidences that specific exhaled nitric 
oxide (FENO) changes, occurring without any change in inflammatory status, are linked to 
specifically located airway caliber changes in the lung periphery. This opens the way for a 
new role for FENO as a functional marker of peripheral airway caliber change. 
  
INTRODUCTION 
Exhaled nitric oxide (NO) essentially results from NO produced in the airway epithelium 
diffusing into the airway lumen during expiration (27). Since NO epithelial production has 
been shown to be triggered by TH2 type airway inflammation (4), it was mainly regarded as a 
non-invasive inflammation monitoring tool in asthma (8). 
However, besides inflammation, acute changes in airway caliber are also a primary feature of 
the asthma pathology and, for more than a decade, several works showed that reductions of 
airway caliber, induced by airways challenges, lead to a dramatic decrease of exhaled nitric 
oxide concentration (FENO) (7, 13, 19, 21). This decrease is even able to mask the impact on 
FENO of an ongoing inflammatory process (12). 
Moreover, different patterns of FENO response to β2-agonists were recently demonstrated in 
asthma patients (20). These distinct behaviors, i.e. stability, significant increase and decrease, 
were related to specific behaviors of ventilation distribution indices, reflecting airway caliber 
changes at different depths of the bronchial tree. So, besides its role as an inflammatory 
marker, FENO is potentially a functional marker of amplitude and location of airway caliber 
changes. 
This emphasizes the importance of understanding how the caliber and location of an airway 
affects the amount of NO penetrating the lumen from the surrounding epithelium. One work 
(32) partly tackled this issue using a model of NO transport incorporating  convection and 
molecular diffusion acting in realistic boundary conditions. However, though informative, this 
model was not designed to simulate the passage of NO from the epithelium to the airway 
lumen and the way lumen caliber changes affect it. 
Therefore, a new model was developed which realistically describes the airway tissue layers: 
smooth muscle, epithelium, and mucus; and the airway caliber changes and which may 
simulate NO transport in the airway lumen as well as in the epithelium wall. This model was 
presented elsewhere in its technical and mathematical aspects (16). The aim of the present 
work is to theoretically assess whether FENO changes after acute manoeuvers reflect 
amplitude and specific location of airway caliber changes and, thus, whether FENO, besides 
its role as an inflammatory marker, may also  be a functional marker. 
METHODS 
The detailed mathematical features of the model used in this paper are extensively described 
in Karamaoun et al. (16). This  model integrates NO production and transport inside the 
epithelium, the muscle and the mucus layers, the excretion from epithelium inside the airway 
lumen and the axial transport of NO in the lumen, the latter feature being derived from Van 
Muylem et al. (31). The geometrical boundaries are derived from Weibel’s symmetrically 
dichotomic model of the lung (33), composed of 24 generations (generation 0 being the 
trachea) and associating one length and one airway diameter to each generation. 
a) NO production, exchange and transport in the bronchial tissues 
From generation 0 to 18, the airways are assumed to be surrounded, from outer side to lumen 
side, by a blood layer, a double tissue layer representing the muscle and the epithelium, and a 
mucus layer as described on Figure 1 (Panel C). 
NO production occurs in the epithelial layer (11), at a constant volumetric rate Pr. 
Once produced, a NO molecule may: 
1) diffuse and be consumed in the epithelium or in the muscle layer, 
2) diffuse and be absorbed by the blood layer, which may be considered as an infinite sink 
due to the high affinity of NO for blood hemoglobin (6), 
3) diffuse through the mucus layer and be excreted inside the airway lumen. 
 
In the ith generation (subscript i), 4 equations describe the transport of NO in the blood (Eq.1), 
the muscle (Eq.2), the epithelium (Eq.3) and the mucus (Eq.4). 
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As depicted Fig.1C, the x axis is a cartesian coordinate normal to the inner airway surface and 
originating at the muscle/blood interface; δM, δE and δμ are the muscle, epithelium and mucus 
thicknesses, respectively. Ct, is the NO concentrations in the tissue, DNO,t is the diffusion 
coefficient of NO in the tissues and mucus assimilated to water,   k is the kinetic constant of 
the reaction consuming NO in the epithelium and muscle tissues. Indeed, this reaction was 
shown to  mainly happen with  superoxide and metalloproteins and to be of the first order 
with respect to NO concentration (3). 
These equations are written using a quasi-steady state approximation, in cartesian coordinates. 
These two assumptions are extensively discussed in Karamaoun et al. (16). 
b) Tissue-air interface 
In the airways, the tissue-air interface corresponds to x= δM+ δE+ δμ. Assuming a 
thermodynamic equilibrium between the NO concentration dissolved in the tissue (Ct) and the 
lumen gaseous (C) NO concentration, the following equation can be written, for the ith 
generation, 
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The equilibrium constant λt:air, is based on the Henry’s constant for NO in water. 
The expression of the NO flux density between the bronchial wall and the gas phase, 
expressed in m.s-1, can thus be established, based on the NO concentration at the interface 
(29), as 
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where γ is a dimension factor allowing to express Jair in m.s
-1 (16). An airway epithelial 
production (Jair) is considered up to generation 18. Beyond, the NO production is assumed to 
come from the alveolar epithelium. 
In the alveoli, for the ith generation, the NO exchange flux density between the alveolar wall 
and the gas phase, expressed in m.s-1, can be written, following Van Muylem et al. (31), as 
?DEF = B2DEF * GDEF!C HDEF,IJIK  (7) 
where Palv is the total alveolar production rate and Ualv is the NO consumption in the alveolar 
tissues. Salv,tot is the total lateral surface of the alveoli, calculated from the Weibel’s data (33), 
assuming an alveolar diameter of 0.2 mm. 
c) Axial NO transport in airway lumen 
Eq. 8 describes the axial diffusion-convection transport for NO in the ith generation. 
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where z is the axial coordinate originating at the alveolar end and t is the time. Q is the air 
flow; Ω, Ω’ and L are the total cross-sectional area (bronchi + alveoli), the airway cross-
sectional area and the length of the generation, respectively. DNO,air is the molecular diffusion 
coefficient of NO in  air. Sair,i and Salv,i are the bronchial and alveolar lateral surfaces of the i
th 
generation, respectively. Jair and Jalv are the NO exchange flux densities from airways (Eq.6) 
and alveoli (Eq.7), respectively. The model is radially expansible during a respiratory cycle. 
Thus Q, Ω’, Ω, Sair, Salv, Jair and Jalv are time dependent. 
The hypotheses on which Eq.8 relies may be found in (31). Solving Eq.8 provides NO 
concentration in any lung generation and for any respiratory phase. 
d) Airway caliber change 
This layered model is a dynamic model, which can be used to simulate an airway caliber 
change in any bronchial generation. The outer radius of an airway is Rm+ δm+δE+δM, Rm being 
the inner radius (see Fig.1C). During a bronchoconstriction, the surrounding muscle is 
contracting. Its shortening leads to a decrease of the outer radius, thus of the radii of each 
layers. Due to the volume conservation in each layer, their thicknesses (δm, δE and δM) 
increase, reducing the inner radius Rm to a larger extent than the outer radius.  
A constriction coefficient β was defined, for the ith generation, as 
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The subscript 0 indicates that the radius is evaluated with no bronchoconstriction occurring. 
Thus, β compares the effective occlusion of the lumen before and after constriction, β = 0 
indicating no constriction, and β = 1 indicating a total occlusion of the bronchus. 
Bronchoconstrictions were simulated by comparing baseline (b=0) to obstructed state (with a 
given b) and bronchodilations were simulated by comparing an obstructed state (with a given 
b) to a non-obstructed state (b=0). In this way, 0<b<1 may be used to characterize the two 
situations. 
e) Numerical simulations 
The NO diffusion-convection equation (Eq.8) is solved numerically in a dimensionless form, 
in order to accelerate and stabilize the computations. An extensive description of the 
equations solving and an access to the associated Mathematica® codes can be found in 
Karamaoun et al. (16). 
The simulations were performed with a 2 s inspiratory time of at a constant flow of 500 ml.s-1 
directly followed by a 20 s expiration at a constant flow of 50 ml.s-1. The values and 
dimensions of the parameters common to all generations are presented in Table 1. 
The following outcomes were considered: 
· The total flux of NO in the ith generation: JawNOi = Jair,i.Sair,i (see Eq.6 and 8). 
· The exhaled nitric oxide concentration, FENO, measured for an expiratory flow equal 
to 50 ml.s-1. FENO was defined as the NO concentration at the onset of the model 
(generation 0) at the end of expiration. The NO production per epithelial volume Pr 
and consumption coefficient k were adjusted in order to yield FENO equal to 15 ppb in 
baseline conditions (i.e. b = 0 and without mucus layer)   
The expiratory flow for FENO computation is in line with the guidelines (2). The latter also 
recommend an inspiration up to total lung capacity (instead of 1 liter) and FENO computed as 
the mean expiratory plateau measured for at least 3 s during an expiration of at least 6 s 
(instead of a single value after 20 s expiration). The impact of the deviations from these 
recommendations on simulated FENO was evaluated in (31) and shown to be trivial. 
RESULTS 
Table 2 summarizes bronchoconstriction simulations, giving the parameter considered, 
whether or not mucus layer or bronchoconstriction was involved, the site on which mucus 
layer or bronchoconstriction is acting, and the associated figure. 
1) Impacts of bronchoconstriction and mucus layer on total NO flux (JawNO) 
Figure 2 shows how a moderate (b=0.5) and a marked (b=0.9) constriction are acting on a 
bronchiole of generation 16, without (Panel A) or with (Panel C) a mucus layer. The red 
arrows allow appreciating JawNO reduction between the epithelium and the airway lumen. 
Panels B and D show JawNO as a function of the generation number in baseline and 
constricted situations with (Panel D) and without (Panel B) a 15 mm thick mucus layer coating 
the epithelium from generations 0 to 18. 
2) Impacts of bronchoconstriction and mucus layer on FENO 
Figure 3 evaluates the distinct effects of bronchoconstriction and mucus layer on FENO. Panel 
A shows the impact of bronchoconstriction (moderate and marked) progressively penetrating 
the bronchial tree free from mucus. Panel B presents the effect of a mucus layer on FENO up 
to a given generation without muscle contraction and for different mucus thicknesses. 
3) Mucus layer and bronchoconstriction interaction effect on FENO 
Figure 4A presents the impact of a marked bronchoconstriction (b=0.9) progressively 
penetrating the bronchial tree whereas a mucus layer is coating generations 0 to 18. Different 
mucus thicknesses (including no mucus) were considered. Figure 4B shows the effect on 
FENO of a marked bronchoconstriction (b=0.9) from generations 0 to 18 whereas a mucus 
layer is progressively coating the bronchial tree. 
4) Distinct response patterns to bronchodilation: 
Figure 5 summarizes the effects of an acute bronchodilation from a baseline constricted state 
(given b) to a non-constricted state (b=0) as a function of mucus thickness (abscissa) and 
baseline bronchoconstriction amplitude (b, ordinate). The solid lines delineate the 
combinations of mucus thickness and b yielding a given FENO change (in % from baseline) 
after bronchodilation. These iso-change lines are interrupted at regular intervals by the 
considered value of FENO change. By example, the lower iso-line on Panel D corresponds to 
a 5% FENO decrease (-5) and the upper line to a 15% decrease (-15). Panels A, B, C differs 
by the area of the bronchial tree on which the bronchodilation applies: from generation 0 to 6 
(central airways), 0 to 15 (up to terminal bronchioles), and 0 to 18 (up to intra-acinar 
airways), respectively, all with a mucus layer coating generation 0 to 18. Panel D is analogous 
to Panel C with a mucus layer coating only generation 0 to 14. Iso-lines are colored as a 
function of FENO behavior:  blue for a non-significant FENO change, green for FENO 
increase of at least 10% and red for FENO decrease of at least 10% after bronchodilation. 
  
DISCUSSION 
 
The simulations presented in this work theoretically support the innovative concept that FENO 
may play a role as a functional marker of acute airway caliber change, not implying change in 
inflammatory status.  Indeed, the present work showed that caliber change may account for 
acute FENO changes evidenced by experimental findings (7, 12, 13, 20, 30). 
 
The first models of NO production and transport, notably accounting for the acute FENO 
dependence on expiratory flow (28), were two-compartment models, i.e. conducting airways 
and alveolar zone, which considered only NO transport by convection (14, 15, 22, 29). 
Further models (26, 31) introduced axial diffusion transport and more realistic boundary 
conditions based on the Weibel’s symmetrical morphometrical model (33). The present model 
(16) is the combination of the axial NO transport model (31) in the airway lumen and of the 
NO diffusion inside the airway tissues surrounding the lumen, the last feature being inspired 
by the Tsoukias et al. epithelial model (29). NO produced in the epithelium is either 
consumed (3), or is transported by diffusion to the blood surrounding the airways (considered 
as an infinite sink), or to the airway lumen where it is excreted through the epithelial surface. 
So, instead of being imposed as in previous models, the NO flux from the epithelium into the 
lumen (currently called JawNO), that enriches alveolar air during expiration, is depending on 
NO production and consumption inside the epithelium tissue and on the physical and 
geometrical properties of the tissue/air interface. Moreover, the present model allows to 
evaluate the effect of an airway caliber change on JawNO and FENO by simulating the 
shortening or lengthening (contraction and relaxation) of the muscle layer surrounding the 
airway which, in turn, impacts the thickness of the epithelial layer and its interface area with 
the airway lumen. A previous model tackled the issue of bronchoconstriction effect on FENO 
(32). However, it was dedicated to axial NO transport and only allowed to present different 
scenarios, resulting from somehow arbitrary assumptions about how JawNO might be 
affected by bronchoconstriction. 
 
The present model shows that JawNO is mechanically, i.e. without NO production change, 
reduced by the decrease of the available epithelial surface through which NO is diffusing, this 
reduction being linked to the bronchoconstriction amplitude. Noteworthy, this effect becomes 
significant only in the small airways where the greater amount of production is concentrated. 
The present model also showed that a mucus layer, not considered in previous models, 
dramatically affects JawNO in the small airways. 
 
Up to the pre-acinar small airways, i.e. generations 15-16, FENO decreases as a function of 
the bronchoconstriction amplitude and location, the deeper acts the bronchoconstriction, the 
greater is the FENO decrease. This was experimentally observed with airway challenges using 
different provocative agents acting on different sites of the peripheral airways (19, 30), with 
comparable degrees of bronchoconstriction in the same subjects. 
When constriction penetrates deeper, the axial molecular diffusion in peripheral airways 
begins to play a crucial role as already emphasized by previous models (26, 31). Indeed, 
during expiration, the NO concentration gradient between pre-acinar bronchioles and the 
alveolar compartment induces a NO diffusion flux, the so-called “back-diffusion”, towards 
alveoli through intra-acinar airways, removing NO molecules from the expiration flow. 
Acinar airway constriction impairs the back-diffusion, by reducing the surface through which 
diffusion occurs, and allows more NO molecules to be expired. Consequently, FENO 
increases despite an overall JawNO decrease. 
 
Besides airway caliber change, a unique feature of the present model is the opportunity to 
consider a mucus layer (assimilated to water) coating the airway epithelium. Indeed, an 
increased and more peripheral mucus layer with goblet cell hyperplasia has been evidenced in 
chronic asthma, even mild, compared to healthy subjects (1, 9). This layer increases the length 
of the diffusion pathway from epithelium to the lumen, resulting in a reduction of both 
JawNO and FENO, even when it occurred in the acinus (up to generation 18). Indeed, even a 
relatively thin layer may impair NO diffusion from the epithelium into the lumen but will not 
greatly affect the axial back diffusion flux. Compared to a situation without mucus and for a 
given airway caliber reduction up to pre-acinar airways, the presence of a mucus layer 
amplifies FENO decrease by 200 to 300%. Moreover, if constriction goes deeper into the 
acinus, no more FENO increase occurs. To allow FENO increase due to intra-acinar 
constriction, the mucus layer has to be no more distal than the 14-15 generations. 
 
Though back-diffusion was evidenced by heliox experiments in healthy subjects (17, 25) and 
in asthma patients (17), a FENO increase due to intra-acinar caliber reduction has never been 
experimentally observed, likely because no currently used provocative agent has such a 
peripheral effect. Fortunately, the mirror manoeuver, i.e. an acute bronchodilation going from 
a baseline constricted state to a non- (or less) constricted state, was shown, by ventilation 
distribution tests, to act up to intra-acinar airways in one third of a cohort of asthma patients. 
These patients concomitantly exhibited a marked FENO decrease. The two other thirds of 
asthma patients exhibited an increase or no change in FENO (20). These observations 
constitute the opportunity to theoretically estimate whether combinations of mucus thickness 
and bronchodilation amplitude may mimic them and whether they may be informative about 
the location of the bronchodilation. This is the purpose of Figure 5 which presents, as contour 
plots, the combinations of mucus thickness and bronchodilation amplitude yielding a given 
FENO change. These combinations were simulated for a central dilation (Fig.5A, generations 
0 to 6), a dilation up to pre-acinar bronchioles (Fig.5B, generations 0 to 15), and up to intra-
acinar airways (Fig.5C, generations 0 to 18). In panels A to C, dilation is associated with 
mucus coating generations 0 to 18 and, panel D, with mucus coating only generations 0 to 14. 
Though some very specific b/mucus thickness combinations may lead to a non-significant 
FENO change after peripheral bronchodilation (Panel B and C), it came out that this feature is 
likely associated with dilation of central airways (blue lines in Fig5A). Conversely, a 
substantial FENO change, whatever the direction of the change, rules out a dilation limited to 
central airways. FENO decrease (red lines) is associated only with intra-acinar airways 
dilation (Fig.5D and 5C), even moderate, which boosts the back-diffusion and, thus, removes 
more NO molecules from the expiratory flow. It is to be noted that this effect is not observed 
if a substantial mucus layer goes further than the 14th generation. FENO increase (green lines) 
is also always linked to peripheral airways. It may be essentially observed with marked 
dilations in pre-acinar airways (Fig.5B), for a large range of mucus thicknesses, but also in 
intra-acinar airways if a thick mucus layer is present. Altogether, the present simulations 
confirmed the link between distinct FENO behaviors that were experimentally evidenced after 
bronchodilation, and specific sites of actions (20), which opens the way to a very simple and 
informative test, i.e. NO measurement before and after acute bronchodilation. Moreover, they 
allowed making assumptions about the presence of a mucus layer in very peripheral airways, 
relevant issue (23) out of the reach of classical lung function tests. 
 
Like all model studies, this work has limitations essentially consisting in over-simplifications. 
We considered a constant epithelial thickness along the bronchial tree and a constant NO 
production per unit epithelial volume. This may have led to overestimate the NO production 
in the very peripheral airways. However, in healthy subjects, Boers et al. (5) found an 
increasing number of Clara cells in terminal to respiratory bronchioles and Shaul et al. (24) 
showed that endothelial NO synthase (eNOS) is expressed in cultured cells of the same 
lineage than Clara cells (NCI-H441 human bronchiolar epithelial cells). This suggests an 
increase of NO production in peripheral airways that is likely amplified in asthma patients 
(30). Finally, the distribution of NO production assumed in the present simulations is very 
close to that deduced from experimental data (18, 30). We also considered a constant mucus 
layer thickness in central as well as in peripheral airways. However, it appeared that the 
mucus layer in the central airways barely affected JawNO or FENO, whatever its thickness. In 
peripheral airways we considered mucus thickness up to 15mm which may seem 
overestimated. Indeed, a 15 mm thick layer would represent ±10% of a 16th generation 
bronchiole lumen area where ±5% is typically described in asthma patients (1). However, we 
assimilated mucus to water, which certainly overestimated the NO diffusivity through the 
mucus. The decrease of NO diffusivity with increased mucus density, not yet established 
should be included in further refinements of the model. 
 
Finally, it is to be noted that this new role of FENO as a marker of airway caliber change after 
an acute intervention is theoretically not limited to asthma. FENO, a biomarker detectable 
even in the absence of inflammation, may be used to detect peripheral airway caliber change 
in other pathological situations, such as chronic obstructive disease, even with active 
smoking, or cystic fibrosis, in which FENO is considered having no or little usefulness as an 
inflammatory marker. These certainly are opportunities for further developments. 
 
In conclusion, the present simulations showed that the link between FENO behavior after an 
airway caliber change and the localization (and the amplitude) of this change is theoretically 
sound. This opens the way for a new area of research in which FENO, besides its undeniable 
utility as an inflammation marker, may play a new role as a peripheral functional marker. 
  
LEGENDS TO THE FIGURES 
Figure 1:  
Schematic representation of an airway: Panel A: transversal cross-section. Panel B: 
longitudinal cross-section. The white zone is the airway lumen; the grey zone is the airway 
wall. The z axis is dedicated to the axial NO transport in the airway lumen. Panel C is a close-
up of the rectangle of Panel A describing the structure of the airway wall. From outer to inner 
part: blood (where NO tissues concentration Ct = 0), muscle (thickness dM, no NO production 
and consumption –k.Ct), epithelium (thickness dE, NO production per unit volume Pr and 
consumption –k.Ct), mucus (thickness dm, no production and no consumption). Rm is the radius 
of the unobstructed part of the airway lumen. The x axis is dedicated to the NO transport in 
the airway wall. Jair is the NO flux density excreted into the airway lumen. 
Figure 2:  
Panel A: cross-section of a generation 16 bronchiole without mucus layer, without 
constriction (b=0), with a moderate constriction (b=0.5), and with a marked constriction 
(b=0.9) from generations 0 to 18. Red arrows are proportional to JawNO. Panel B: JawNO as 
a function of the generation number for the constriction depicted on Panel A. Panels C and D: 
analogous to Panels A and B, with a mucus layer of 15 µm thickness covering generations 0 
to 18. 
Figure 3: 
Panel A: FENO change (in % of baseline) when a moderate (grey line) or a marked (black 
line) bronchoconstriction penetrates the bronchial tree (from generation 0 up to …) free from 
mucus. The baseline situation is b=0. Panel B: FENO change (in % of baseline) when a mucus 
layer of 5 (light grey), 10 (dark grey) and 15 (black) mm thickness progressively coats the 
bronchial tree (from generation 0 up to …) without muscle length change (b=0). The baseline 
situation is no mucus layer. 
Figure 4: 
Panel A: FENO change (in % of baseline) due to a marked bronchoconstriction (b=0.9) 
penetrating the bronchial tree (from generation 0 up to …) either without mucus (dashed line) 
or with a mucus layer of 5 (light grey), 10 (dark grey) and 15 (black) µm thickness coating the 
generations 0 to 18. Baseline situation is b=0 and mucus layer, if any. Panel B: FENO change 
(in % of baseline) due to a marked bronchoconstriction (b=0.9) from generations 0 to 18 
when a mucus layer of 5 (light grey), 10 (dark grey) and 15 (black) µm thickness 
progressively coats the bronchial tree (from generation 0 up to …). Baseline situation is b=0 
and mucus layer up to the given generation. 
Figure 5: 
Effect of an acute bronchodilation on FENO from a baseline constricted state to a non-
constricted state. Panels A-D: contour plots of iso-DFENO% as a function of mucus thickness 
and baseline bronchoconstriction amplitude (b). Panels A, B, C correspond to a baseline 
bronchoconstriction from generation 0 to 6, 0 to 15, and 0 to 18, respectively, with a mucus 
layer coating generation 0 to 18. Panel D is analogous to Panel C with a mucus layer coating 
generation 0 to 14. Color lines delineate the mucus thickness/b combinations corresponding to 
a non-significant FENO change (blue lines), a FENO increase (green lines) and a FENO 
decrease (red lines) after bronchodilation. 
  
Table 1 
Parameter Description Value Units References 
δE,0 Airway epithelium thickness 0.0015 cm (10) 
δM,0 Muscle thickness 0.0030 cm (10) 
DNO,air NO diffusion coefficient in air 0.217 cm
2.s-1 (31) 
DNO,t NO diffusion coefficient in tissues 3.3 10
-5 cm2.s-1 (29) 
γ Correction factor 2.545 104 cm3.mol-1 (16) 
k Kinetic constant of NO 
consumption in the tissues 
2.001 s-1 Adapted from (29) 
λt:air Tissue/air equilibrium constant 1.64 10
-6 molNO.cm-3 Adapted from (29) 
Pr NO epithelial production per unit 
tissue volume 
5.17 10-12 molNO.cm-3.s-1 Adapted from (29) 
Palv Total NO alveolar production 3.167 10
-6 mlNO.s-1 (22) 
Ualv NO consumption in alveolar 
tissues 
1558 cm3.s-1 (22) 
 
  
Table 2: Bronchoconstriction simulations summary 
Figure Outcome Mucus 
thickness 
Localization* Bronchoconstriction Localization* 
Fig2A/2B JawNO no - b=0.5; b=0.9 0 - 18 
Fig2C/2D JawNO 5, 10, 15mm 0 - 18 b=0.5; b=0.9 0 - 18 
Fig3A FENO no - b=0.5; b=0.9 0 – n
** 
Fig3B FENO 5, 10, 15mm 0 – n
** no - 
Fig4A FENO 5, 10, 15mm 0 - 18 b=0.9 0 - 18 
Fig4B FENO 5, 10, 15mm 0 – n
** b=0.9 0 - 18 
*: generation number where mucus layer and/or bronchoconstriction are/is present; **: from generation 0 up 
to a given generation n. 
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